Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 29;14(1):20054.
doi: 10.1038/s41598-024-69637-4.

Dispensed prescription medications and short-term risk of pulmonary embolism in Norway and Sweden

Affiliations

Dispensed prescription medications and short-term risk of pulmonary embolism in Norway and Sweden

Dagfinn Aune et al. Sci Rep. .

Abstract

Scandinavian electronic health-care registers provide a unique setting to investigate potential unidentified side effects of drugs. We analysed the association between prescription drugs dispensed in Norway and Sweden and the short-term risk of developing pulmonary embolism. A total of 12,104 pulmonary embolism cases were identified from patient- and cause-of-death registries in Norway (2004-2014) and 36,088 in Sweden (2005-2014). A case-crossover design was used to compare individual drugs dispensed 1-30 days before the date of pulmonary embolism diagnosis with dispensation in a 61-90 day time-window, while controlling for the receipt of other drugs. A BOLASSO approach was used to select drugs that were associated with short-term risk of pulmonary embolism. Thirty-eight drugs were associated with pulmonary embolism in the combined analysis of the Norwegian and Swedish data. Drugs associated with increased risk of pulmonary embolism included certain proton-pump inhibitors, antibiotics, antithrombotics, vasodilators, furosemide, anti-varicose medications, corticosteroids, immunostimulants (pegfilgrastim), opioids, analgesics, anxiolytics, antidepressants, antiprotozoals, and drugs for cough and colds. Mineral supplements, hydrochlorothiazide and potassium-sparing agents, beta-blockers, angiotensin 2 receptor blockers, statins, and methotrexate were associated with lower risk. Most associations persisted, and several additional drugs were associated, with pulmonary embolism when using a longer time window of 90 days instead of 30 days. These results provide exploratory, pharmacopeia-wide evidence of medications that may increase or decrease the risk of pulmonary embolism. Some of these findings were expected based on the drugs' indications, while others are novel and require further study as potentially modifiable precipitants of pulmonary embolism.

Keywords: Drugs; Medications; Pulmonary embolism.

PubMed Disclaimer

Conflict of interest statement

Rickard Ljung is employed at the Swedish Medical Products Agency, Uppsala, Sweden. The views expressed in this paper do not necessarily represent the views of the Government agency. The remaining authors have nothing to disclose. The interpretation and reporting of these data are the sole responsibility of the authors, and no endorsement by the Department of Health Registries is intended nor should be inferred.

Figures

Figure 1
Figure 1
Case-crossover analysis of dispensed prescription medication use and risk of pulmonary embolism. The above plot illustrates (A) unique drug types which were selected in Norway, (B) unique drug types which were selected in Sweden, and (C) 59 drugs which were common hits from both the countries. Y-axis displays relative risk on the log scale, X-axis displays all the prescribed drugs studied grouped by the anatomical therapeutic chemical (ATC) classification.

References

    1. Turetz, M., Sideris, A. T., Friedman, O. A., Triphathi, N. & Horowitz, J. M. Epidemiology, pathophysiology, and natural history of pulmonary embolism. Semin. Intervent. Radiol.35, 92–98 (2018). 10.1055/s-0038-1642036 - DOI - PMC - PubMed
    1. Barco, S. et al. Global reporting of pulmonary embolism-related deaths in the World Health Organization mortality database: Vital registration data from 123 countries. Res. Pract. Thromb. Haemost.5, e12520 (2021). 10.1002/rth2.12520 - DOI - PMC - PubMed
    1. Dentali, F. et al. Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy. Thromb. Haemost.115, 399–405 (2016). 10.1160/th15-02-0172 - DOI - PubMed
    1. Arshad, N., Isaksen, T., Hansen, J. B. & Brækkan, S. K. Time trends in incidence rates of venous thromboembolism in a large cohort recruited from the general population. Eur. J. Epidemiol.32, 299–305 (2017). 10.1007/s10654-017-0238-y - DOI - PubMed
    1. Raptis, D. G., Gourgoulianis, K. I., Daniil, Z. & Malli, F. Time trends for pulmonary embolism incidence in Greece. Thromb. J.18, 1 (2020). 10.1186/s12959-020-0215-7 - DOI - PMC - PubMed

Substances

LinkOut - more resources